Evidence map›Paper›PMID 25505573›Full record

ArticlePharmacology research & perspectives2014

Nigramide J is a novel potent inverse agonist of the human constitutive androstane receptor.

Yuichiro Kanno, Nobuaki Tanuma, Tomofumi Yatsu, Wei Li, Kazuo Koike, Yoshio Inouye

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Small-molecule modulators of the constitutive androstane receptor.Expert opinion on drug metabolism & toxicology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yuichiro KannoFaculty of Pharmaceutical Sciences, Toho University Miyama 2-2-1, Funabashi, Chiba, 274-8510, Japan.
Nobuaki TanumaFaculty of Pharmaceutical Sciences, Toho University Miyama 2-2-1, Funabashi, Chiba, 274-8510, Japan.
Tomofumi YatsuFaculty of Pharmaceutical Sciences, Toho University Miyama 2-2-1, Funabashi, Chiba, 274-8510, Japan.
Wei LiFaculty of Pharmaceutical Sciences, Toho University Miyama 2-2-1, Funabashi, Chiba, 274-8510, Japan.
Kazuo KoikeFaculty of Pharmaceutical Sciences, Toho University Miyama 2-2-1, Funabashi, Chiba, 274-8510, Japan.
Yoshio InouyeFaculty of Pharmaceutical Sciences, Toho University Miyama 2-2-1, Funabashi, Chiba, 274-8510, Japan.
Toho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The constitutive androstane receptor (CAR, NR1I3) is very important for drug development and for understanding pharmacokinetic drug-drug interactions. We screened by mammalian one hybrid assay among natural compounds to discover novel ligands of human constitutive androstane receptor (hCAR). hCAR transcriptional activity was measured by luciferase assay and mRNA levels of CYP2B6 and CYP3A4 in HepTR-hCAR cells and human primary hepatocytes were measured by real-time RT-PCR. Nigramide J (NJ) whose efficacy is comparable to those of hitherto known inverse agonists such as clotrimazole, PK11195, and ethinylestradiol. NJ is a naturally occurring cyclohexane-type amide alkaloid that was isolated from the roots of Piper nigrum. The suppressive effect of NJ on the CAR-dependent transcriptional activity was found to be species specific, in the descending order of hCAR, rat CAR, and mouse CAR. The unliganded hCAR-dependent transactivation of reporter and endogenous genes was suppressed by NJ at concentrations higher than 5 μmol/L. The ligand-binding cavity of hCAR was shared by NJ and CITCO, because they were competitive in the binding to hCAR. NJ interfered with the interaction of hCAR with coactivator SRC-1, but not with its interaction with the corepressor NCoR1. Furthermore, NJ is agonist of human pregnane X receptor (hPXR). NJ is a dual ligand of hCAR and hPXR, being an agonist of hPXR and an inverse agonist of hCAR.

Indexed as

Constitutive androstane receptorinverse agonistnigramidenuclear receptor

Identifiers

PMID25505573
PMCPMC4186399
OpenAlexW2031266088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.